Mogling Bio

What Mogling Bio does

Mogling Bio is a preclinical-stage biopharmaceutical company founded in 2022 that develops pharmacological approaches to rejuvenate aged hematopoietic stem cells. The company's core asset is CASIN, a small-molecule CDC42 inhibitor developed over fifteen years by scientific co-founders Prof. Yi Zheng (Cincinnati Children's Hospital Medical Center) and Prof. Hartmut Geiger (Ulm University). The underlying biology targets the age-related hyperactivity of the small GTPase CDC42, which disrupts cellular architecture in stem cells; CASIN is designed to normalize CDC42 activity and restore structural and functional integrity in aged hematopoietic stem cells, with downstream potential applications in blood diseases, leukemia, immune dysfunction, osteoporosis, and neurodegeneration.

Mogling Bio holds an exclusive global license from Cincinnati Children's Hospital Medical Center to develop, manufacture, and commercialize CASIN worldwide. The company is privately held, headquartered in Cincinnati, Ohio (with legal domicile in Wilmington, Delaware), and operates with 1–10 employees. Its sole disclosed institutional investor is Kizoo Technology Capital, which led the seed round in October 2022. Leadership combines the two scientific founders with CEO Jürgen Reeß (formerly SVP at Boehringer Ingelheim), CDO Anne Eldrup, and CSO Tim Tracy, supported by a Scientific Advisory Board and Board of Directors with pharma development and cell therapy expertise.

The business model is not yet revenue-generating. Mogling Bio pursues enterprise business development through licensing and co-development partnerships with pharmaceutical companies, supported by scientific publication, conference presence (including the Rejuvenation Startup Summit 2024), and a corporate website. Future monetization is expected to flow through licensing royalties, milestone payments, or acquisition by a larger pharmaceutical partner once the asset advances through preclinical and clinical development.

Name

Mogling Bio

Legal name

Mogling Bio Inc.

Website

https://moglingbio.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Mogling Bio is a preclinical-stage biopharmaceutical company developing CASIN, a CDC42 inhibitor that rejuvenates aged hematopoietic stem cells, with applications in blood diseases, immune dysfunction, and age-related disorders. The asset is exclusively licensed from Cincinnati Children's Hospital Medical Center and seed-funded by Kizoo Technology Capital.

Ownership category

akta.pro rank

Product category

Rejuvenation Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE)

akta.pro secondary industries

Oncology & Hematology Pharmaceuticals (HLAIAAAC), Hematology Specialty Pharmaceuticals (Non-malignant) (HLAIACAI), Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

Keywords

• Stem cell rejuvenation
• CDC42 inhibitors
• Preclinical biopharmaceuticals
• Age-related disease therapeutics
• Hematopoietic stem cell therapy

Headquarters

HQ city

Wilmington

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations

Revenue model

1. Not yet revenue-generating: Mogling Bio is a preclinical stage biopharmaceutical company. As of 2022-2023, the company is focused on developing CASIN for rejuvenation of hematopoietic stem cells and has not yet generated revenue from product sales.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Mogling Bio develops CASIN, a proprietary pharmacological CDC42 inhibitor that rejuvenates aged hematopoietic stem cells by normalizing age-related hyperactivity of the Cdc42 GTPase. The compound is being advanced preclinically for applications in blood disorders, immune dysfunction, osteoporosis, neurodegeneration, and leukemia/multiple myeloma combination therapy. The company holds an exclusive worldwide license to CASIN from Cincinnati Children's Hospital Medical Center and intends to monetize through out-licensing to pharmaceutical partners.

Product overview

Mogling Bio is a preclinical-stage biopharmaceutical company developing new pharmacological approaches to rejuvenate old stem cells of the hematopoietic (blood cell formation) system. The company's core technology centers on CASIN, a CDC42 inhibitor that normalizes CDC42 activity to restore structure and function in aged stem cells. Aging causes stem cells to lose their normal structure through increased activity of the protein CDC42, leading to decreased production and quality of blood and immune cells. By targeting CDC42, Mogling Bio aims to develop treatments for blood diseases, immune dysfunction, osteoporosis, and neurodegeneration, ultimately with the goal of extending healthspan.

Differentiator

Problem solved

Functional benefit

Products and services

• CASIN (CDC42 Inhibitor) CASIN is a small-molecule CDC42 inhibitor that normalizes age-related hyperactivity of the Cdc42 GTPase to restore cellular architecture and rejuvenate hematopoietic stem cell function. It is being advanced preclinically for blood diseases, immune dysfunction, osteoporosis, neurodegeneration, and as a combination agent in leukemia and multiple myeloma.

Quantifiable outcome

• Aged HSCs treated with CASIN reestablished an immune system similar to that of young animals, capable of mounting a strong immune response to vaccination

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

One partnership is on record.

• Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development PartnerMogling Bio entered into a global exclusive licensing agreement with Cincinnati Children's Hospital Medical Center for CASIN, a CDC42 inhibitor being developed for rejuvenation of hematopoietic stem cells. The technology was developed by Prof. Yi Zheng and Prof. Hartmut Geiger over 15 years of research.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

Direct peers

• Turn Biotechnologies: Preclinical-stage rejuvenation biotech developing mRNA-based cellular reprogramming to restore youthful cellular function. Directly comparable stage, modality philosophy (small intervention to rejuvenate), and target indications (age-related disease) to Mogling Bio.
• Unity Biotechnology: Public clinical-stage biotech developing senolytics and other therapeutics that eliminate or rejuvenate aged/senescent cells, directly overlapping Mogling Bio's mission of restoring function to aged cells. Same target space (cellular aging) with different mechanism.
• Life Biosciences: Private longevity biotech developing therapeutics targeting mitochondrial dysfunction and other aging pathways. Directly comparable as a private, well-funded player in the cellular rejuvenation space serving multiple age-related indications.
• Altos Labs: Well-capitalized ($3B raised) cellular rejuvenation company pursuing Yamanaka-factor-based cellular reprogramming to reverse aging. Same rejuvenation thesis as Mogling Bio but operating at far greater scale and capital intensity.
• Kurome Therapeutics: Cincinnati-based hematology biotech. Mogling Bio SAB member Jan S. Rosenbaum is an executive expert at Kurome, and both target blood/bone-marrow-related indications from the same regional academic network.

Emerging players

• NewLimit: Preclinical biotech developing epigenetic reprogramming therapies to rejuvenate aged cells. Same broader rejuvenation thesis as Mogling Bio with a different (epigenetic) mechanism; smaller team profile is similar.
• Retro Biosciences: Sam Altman-backed preclinical biotech pursuing cellular reprogramming and autophagy-based rejuvenation therapies. Comparable stage and rejuvenation thesis, but with substantially more capital and ambition than Mogling Bio.
• Insilico Medicine: AI-driven biotech with a visible aging/geroscience pipeline alongside broader drug discovery. Comparable as a preclinical/early-stage aging therapeutics developer with multiple internal programs.
• Aeovian Pharmaceuticals: Early-stage biotech developing therapeutics that target aging-related cellular dysfunction. Comparable as a small preclinical-focused rejuvenation player pursuing similar age-related disease indications.

Broad incumbents

• Calico Labs: Alphabet/Google-backed aging research and drug development company. Operates broadly across aging biology at significantly larger scale; competing for pharma partnerships and rejuvenation talent overlap with Mogling Bio's mission.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

• YouTubeyoutube.com/results?search_query=MoglingBio
• LinkedInlinkedin.com/company/moglingbio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mogling Bio